News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Industry Trends

>
  • IR Licensing and Partnerships

Latest News

Earned Media and ASCO: Provide Context Beyond the Data
Earned Media and ASCO: Provide Context Beyond the Data
By Michael Christel

May 13th 2025

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
By Don Tracy, Associate Editor

May 13th 2025

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D
By Don Tracy, Associate Editor

April 28th 2025

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation
Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation
By Don Tracy, Associate Editor

April 22nd 2025

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Improving Your Earned Media Strategy: Tips and Insights
Improving Your Earned Media Strategy: Tips and Insights
By Michael Christel

April 16th 2025

Introducing a new series highlighting ways pharma companies can up their game in winning earned media—and ultimately deliver greater impact and value from their messaging.

More News


Site Logo

The Fundamental Pillars of Good Forecasting

Maiko Midena
July 11th 2017

Maiko Midena discusses the key fundamentals to success when it comes to forecasting with large multinational pharmaceutical organizations.


Pharm Exec's Top 50 Companies 2017

Pharm Exec's Top 50 Companies 2017

Michael Christel
June 28th 2017

Pharm Exec's 17th annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.


Site Logo

Could Valeant Pharmaceuticals Have Gifted Teva its "Biggest Commercial Hope"?

Duncan Clark
June 26th 2017

Intellectual property analysis of one recently approved drug shows how Valiant might have missed out on at least one vital acquisition opportunity. Duncan Clark reports.


Sun, Sand and Drugs: How a Beach Town Became a Biotech Hub

Sun, Sand and Drugs: How a Beach Town Became a Biotech Hub

Bob Swindell
June 15th 2017

Bob Swindell explains how Greater Fort Lauderdale has spent the past few years quietly assembling one of the most dynamic pharmaceutical clusters in the country.


Brand of the Year: A Retrospective

Brand of the Year: A Retrospective

Christen Harm
May 17th 2017

With this year marking our 11th installment, we look back on Pharm Exec's first 10 Brands of the Year-why they were chosen and the challenges, changes, and successes since.


Pharma and Biotech Markets: Mostly Sunny, But An Uncertain Forecast

Pharma and Biotech Markets: Mostly Sunny, But An Uncertain Forecast

Peter Young, Young & Partners
May 9th 2017

Pharm Exec's Editorial Advisory Board member, Peter Young, cover a summary of the strategic issues facing the biopharma industry, but goes on to tell the story of what happened last year and this first quarter in terms of the stock market, M&A and financing (including IPOs) activity, where it is headed, and the implications for senior management.


Path of Uncertainty: Pharm Exec’s 2017 Industry Forecast

Path of Uncertainty: Pharm Exec’s 2017 Industry Forecast

Julian Upton;Casey McDonald
February 3rd 2017

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.


Pharma and Biotech Markets: Challenges and Opportunities

Pharma and Biotech Markets: Challenges and Opportunities

Peter Young
January 18th 2017

With the soaring valuations of companies in the public and M&A markets now seemingly a distant memory, the challenge for pharma and biotech business will be choosing just the right overall mix of M&A, licensing, and partnering.


Pharma M&A Market: Latest Challenges and Opportunities

Peter Young
January 3rd 2017

For ethical pharma companies, there continues to be a wide variety of tools to acquire revenues and pipeline drugs, but the valuations are challenging, writes Peter Young.


Executive Pay and Innovation

Executive Pay and Innovation

Carl Sjostrom and Ian Wilcox
December 9th 2016

How the need for biopharma innovation extends to questions around executive compensation.


Bill thumbnail.jpg

Rise of the Vox Populi

William Looney
September 7th 2016

Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks-a realization that has slowly creeped into their business planning.


Pharm Exec's 15th Annual Industry Audit

Pharm Exec's 15th Annual Industry Audit

Bill Trombetta
August 31st 2016

As market headwinds persist, our latest industry review of shareholder value reveals a sharp performance differential between companies that pursue a strategy of specialized therapeutic focus and those that continue to rely on line diversity, size and scale.


Editorial chart.png

The Industry Audit: Fifteen Years Right

William Looney
August 29th 2016

With our annual Industry Audit marking its 15th year, we decided to compare 2002 approaches in boosting shareholder value to those of today. The fall in one particular performance metric is telling.


Pharm Exec's Annual Press Audit 2016

Pharm Exec's Annual Press Audit 2016

George Sillup and Stephen J. Porth
July 20th 2016

George Sillup and Stephen J. Porth identify the “hot button” issues attracting media attention in 2015.


Casey thumbnail.jpg

Pill Counters

Casey McDonald
July 12th 2016

Pharm Exec adds up some interesting figures from recent industry news.


Diversity and Inclusion: A Pharma 50 Perspective

Diversity and Inclusion: A Pharma 50 Perspective

Waseem Noor;Saule Serikova
June 23rd 2016

Biopharma’s diversity commitment remains a work in progress but the benefits-in measurable ROI-are increasingly clear.


Pharma and Biotech Financial Outlook: Hazy

Pharma and Biotech Financial Outlook: Hazy

Peter Young
June 13th 2016

Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull - or a permanent drop? Peter Young reports.


28fdd05.jpg

Pharma 2016: Hot Topics, Burning Questions

Clifford Kalb
January 29th 2016

Pharm Exec Editorial Advisory Board member Cliff Kalb poses some of the pertinent questions he expects the pharma industry will be asking this year.


From the Editor: Demographic of Distress

From the Editor: Demographic of Distress

William Looney
December 7th 2015

A new discipline-population health-contests disease treatment as an end in itself. It asks: besides advancing the science of medicine, what do biopharmaceuticals actually do to improve health overall?


Tech Giants Collaborate and Disrupt in Life Sciences Industry

Anaïs Frappé
November 23rd 2015

As tech giants, enter the life sciences industry, healthcare companies should adapt their business model and embark with these new players on a more ambitious, personalized, and preventive healthcare strategy.


Precision Medicine's March to Market: 'Pairing' for Success

Precision Medicine's March to Market: 'Pairing' for Success

Kevin Barnett;Nathan Lyman;Kun Lee;Jeff Liepman
November 6th 2015

In the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.


Mike-Straw-image.jpg

Pharma Boards in the Era of Hostile Takeovers

Mike Straw
October 19th 2015

With hostile takeovers on the rise, Mike Straw argues that pharma boards have a huge role to play in managing the people issues.


Knowledge is Value: Navigating Biopharma’s New IP Terrain

Knowledge is Value: Navigating Biopharma’s New IP Terrain

William Looney
October 11th 2015

Driven by knowledge advances and the importance of a more collaborative commercial model, intellectual property (IP) has morphed from an arcane, specialized function dominated by technicians to a showcase strategic priority of the “c-suite.” This trend is hardly restricted to the life sciences. In fact, some of the most creative work in using IP tools to extract more value from knowledge assets is taking place among businesses that operate across multiple sectors.


Pharm Exec's 14th Annual Industry Audit

Pharm Exec's 14th Annual Industry Audit

Bill Trombetta
September 15th 2015

After a sharp spike in revenues, this year’s audit finds our 25 companies doubling down to secure the operational efficiencies that promise to better align with an increasingly tightfisted payer community. Never before has market relevance been so firmly linked to customer reputation.


Audit Alliterations

William Looney
September 8th 2015

A closer look at our Industry Audit numbers hints to a clear divide between two alternative strategies for long-term growth: scale versus focus.


Top Trends in Biopharmaceutical Manufacturing 2015

Top Trends in Biopharmaceutical Manufacturing 2015

Randi Hernandez
July 23rd 2015

New cell-culture techniques, biomanufacturing formats, and the expansion of single-use applications are driving rapid change in the biopharma market.


Taking Flight: Pharm Exec's Top 50 Pharma Companies 2015

Taking Flight: Pharm Exec's Top 50 Pharma Companies 2015

Ben Comer;Michael Swanick;David Hole
July 14th 2015

 Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.    


Bill thumbnail.jpg

The Human Chain: The Emerging Pharma Leaders

William Looney
July 1st 2015

Amid the release of our eighth list of Emerging Pharma Leaders, it's fitting to take a look at the trends and values that will determine true leadership in big Pharma in the years ahead.


Pharma M&A and Financial Trends: The Frenzy and Risks Escalate

Pharma M&A and Financial Trends: The Frenzy and Risks Escalate

Peter Young
June 10th 2015

The pharma industry is making progress and going through a frenzy of activity on the strategic, business, M&A and financial fronts, writes Peter Young.


Site Logo

HBA's Woman of the Year Awards

Casey McDonald
May 15th 2015

Casey McDonald reports on yesterday's Healthcare Businesswoman’s AssociationWoman of the Year award ceremony in New York

<1
...
1213141516171819>
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.